United States · FDA National Drug Code directory

Lubiprostone

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
71205-831_4aed57d0-99d8-424e-a1c7-0cd8a31a66cf
Product NDC
71205-831
Form
CAPSULE, GELATIN COATED
Composition / generic term
lubiprostone
Labeler
Proficient Rx LP
Marketing category
NDA AUTHORIZED GENERIC
Marketing start / end (source format)
20230101
Source listing expiry
20261231

Source-listed ingredients

  • LUBIPROSTONE — 8 ug/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 100 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-00) · 71205-831-00
  • 1000 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-11) · 71205-831-11
  • 30 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-30) · 71205-831-30
  • 500 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-55) · 71205-831-55
  • 60 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-60) · 71205-831-60
  • 240 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-64) · 71205-831-64
  • 270 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-67) · 71205-831-67
  • 120 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-72) · 71205-831-72
  • 180 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-78) · 71205-831-78
  • 90 CAPSULE, GELATIN COATED in 1 BOTTLE (71205-831-90) · 71205-831-90

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →
Lubiprostone — United States | Molindra Medicines